PCSK9 and atherosclerosis: A meta-analysis of 19 randomized trials reported reduced CV morbidity in secondary-prevention patients having a history of ASCVD (CAD, peripheral artery disease, or cerebrovascular disease) with intensified statin therapy alone or added to PCSK9 inhibitors or ezetimibe [78].